


**Program:** Center for Veterinary Medicine

**Agency:** Department of Health and Human Services

**Bureau:** Food and Drug Administration



**Key Performance Measures**

**Year Target Actual**

Measure	Year	Target	Actual
Long-term Measure: Measures under development			
Annual Measure: Percentage of new animal drug applications reviewed and "acted on" within 180 days of receipt	2000	73%	74%
	2001	75%	50%
	2002	50%	
Annual Measure: Percentage of registered animal drug and feed establishments inspected (Statutory performance target is 50%.)	1999	27%	25%
	2000	27%	39%
	2001	50%	37%
	2004	50%	

**Rating:** Results Not Demonstrated

**Program Type:** Regulatory

**Program Summary:**

The Center for Veterinary Medicine (CVM) regulates the manufacture and distribution of food additives and drugs given to animals. CVM makes sure such additives and drugs are safe for animals and humans who may consume the animals or their products (such as milk).

Findings from the PART assessment include the following:

1. The creation of long-term outcome goals would allow for measurement of program performance, and would strengthen CVM accountability and results.
2. CVM is improving the review of new animal drugs. Years of poor performance created work backlogs, which resulted in the establishment of performance targets that were far from ambitious. CVM identified this weakness, and established an annual performance goal aimed at eliminating backlogs in the review of new animal drugs.
3. CVM has exhibited outstanding performance in the inspection of rendering establishments as a part of CVM efforts to prevent the introduction of Bovine Spongiform Encephalopathy (BSE, or "Mad Cow Disease") in the United States.
4. Financial management is sound, and managers take meaningful steps to address management weaknesses.
5. CVM achieved a high score for their Planning efforts. CVM's list of annual performance goals allows for measurement of performance results. Long-term outcome goals would improve strategic planning at CVM.
6. CVM achieved a high score in Purpose. CVM's efficient and effective regulatory strategy to prevent the introduction of BSE into the United States underscores the relevance of CVM's responsibilities.

In response to these findings, the Administration will:

1. Establish new, measurable long term performance goals for CVM.
2. Improve current annual performance goals for the review of new products. New annual performance goals for the review of new animal drugs will be revised to measure time to completion of FDA review, a critical milestone in the review process.
3. Propose the authorization of new user fees to support performance enhancements in the review of new animal drugs. More ambitious performance goals for animal drug reviews are under development.

**Program Funding Level (in millions of dollars)**

2002 Actual	2003 Estimate	2004 Estimate
86	89	91